MedImpact Includes MedEmpower Fuel™ Health and Wellness App as a Standard Part of Pharmacy Benefit Services
MedImpact includes MedEmpower Fuel™ #health and #wellness app as a standard part of pharmacy benefit services. Share
'By embedding MedEmpower Fuel as a benefit, MedImpact is looking beyond the prescription to deliver a solution that not only enhances member satisfaction and health outcomes, but also helps payers improve member health and reduce overall healthcare costs,' said Zach Johnson, MedImpact Executive Vice President. 'It's personalized, engaging, and innovative—exactly what's needed to drive sustainable change.'
This offering comes at a critical time. The widespread adoption of GLP-1 medications for obesity and diabetes has placed a heavy and growing financial burden on payers. These medications, while effective, come with significant long-term cost implications. If a patient with obesity discontinues treatment—as at least half do within the first year—they typically regain the lost weight, according to the Journal of the American Medical Association (JAMA).
The MedEmpower Fuel app empowers individuals to make healthier choices by providing personalized meal planning, activity tracking, and behavioral coaching—all designed to support weight management, chronic disease prevention, and medication adherence. By integrating this app into the pharmacy benefit design, MedImpact aims to reduce long-term healthcare costs by addressing the root causes of high-cost conditions.
In addition to the nutrition and wellness platform now a part of MedImpact's core pharmacy benefit, MedEmpower Fuel also offers clinical condition management programs tailored specifically for people with hypertension, cancer, autoimmune disease, and behavioral health challenges with one-on-one coaching. And while these supplemental bundles are available to health plans at an additional cost, they provide personalized clinical support to people with the most complex and costly health challenges.
MedEmpower Fuel is one part of MedImpact's enterprise-wide strategy to deliver lower costs and improved access for members, payers, and pharmacies. This includes providing wholesale access to biosimilars to any specialty pharmacy, more flexible and cost-effective formulary choices, and price guarantees, among other features. An independent company with scale, clinical strength, and advanced technology, MedImpact is uniquely able—and driven—to offer this combination of solutions, technology, accountability, and transparency.
'The status quo is just not enough,' continued Johnson. 'MedEmpower Fuel reflects our commitment to innovation, integration, and impact—blending pharmacy, behavioral, and nutritional insights into one seamless experience that supports members where they are.'
MedEmpower Fuel is immediately available to MedImpact clients.
About MedImpact
San Diego-based MedImpact Healthcare Systems, Inc. is the nation's largest independent health solutions, technology, and pharmacy benefit management provider. For 35 years, MedImpact has helped commercial and government healthcare payers improve member health, manage benefits, and reduce drug costs. Today, MedImpact serves more than 20 million members and processes more than $40 billion in pharmacy transactions annually. To learn more, visit us online, follow us on LinkedIn, or contact us at info@MedImpact.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
22 minutes ago
- Business Wire
SMSbiotech Initiates Groundbreaking Phase 1 Human Clinical Trial for COPD
MELBOURNE, Australia--(BUSINESS WIRE)--SMSbiotech, a San Diego–based leader in regenerative medicine, today announced the initiation of its first-in-human Phase 1 clinical trial for Chronic Obstructive Pulmonary Disease (COPD). This milestone marks the transition of years of dedicated research into clinical development, with the goal of delivering a transformative therapy for millions living with this debilitating lung condition. The initiation of our Phase 1 trial for COPD is a profound moment for SMSbiotech and, more importantly, for the millions of patients yearning for better treatment options. Share On July 11, 2025, at Veritus Research in Melbourne, Australia, the first dose of SMSbiotech's novel therapeutic candidate was administered to the inaugural patient. The Phase 1 study, titled 'A study to investigate small mobile stem cells (SMS cells) in participants aged 39 to 69 years with chronic obstructive pulmonary disease,' will enroll 18 COPD patients. The trial is designed to evaluate the safety and preliminary efficacy of SMSbiotech's Small Mobile Stem (SMS) cells —a unique, healthy, adult blood-derived cell population discovered and named by SMSbiotech. Unlike traditional treatments, SMS cells are designed to regenerate damaged lung tissue. The off-the-shelf, non-invasive therapy is administered directly to the lungs through a nebulizer. Preclinical studies demonstrated significant restoration of lung function in as little as 10 days. The study duration is expected to be 15 months. 'The initiation of our Phase 1 trial for COPD is a profound moment for SMSbiotech and, more importantly, for the millions of patients yearning for better treatment options,' said Dr. Abdulkader Rahmo, President of SMSbiotech. 'We are also encouraged to report that the first two sentinel patients have been dosed, initial safety data has been received, and the trial can now move forward—an important validation step as we continue this study. We are immensely optimistic about the potential of our Small Mobile Stem cell therapy to not only manage COPD symptoms but to fundamentally alter the disease's progression and potentially reverse its devastating effects. We believe this represents a new dawn for respiratory medicine, offering the promise of a future where patients can breathe easier and live fuller lives.' The trial received regulatory approval from the Therapeutic Goods Administration (TGA), Australia's regulatory authority equivalent to the U.S. Food and Drug Administration (FDA). SMSbiotech has filed 16 patents and received 7 granted patents for its technology. Pending sufficient safety data from this trial, the company plans to evaluate compassionate use applications. Encouraged by promising preclinical data, SMSbiotech is also investigating applications in orthopedics and other therapeutic areas. For more information about this clinical trial, please visit the Australian New Zealand Clinical Trials Registry at: About SMSbiotech SMSbiotech is a regenerative medicine company dedicated to advancing breakthrough therapies that restore tissue function and transform patient care. Leveraging its proprietary Small Mobile Stem (SMS) cell technology, SMSbiotech is focused on developing novel treatments for COPD and other debilitating diseases.
Business Wire
22 minutes ago
- Business Wire
Blue Cross Blue Shield of North Dakota to Join Cambia Health Solutions as Newest Affiliated Single-State Blue Plan
PORTLAND, Ore. & FARGO, N.D.--(BUSINESS WIRE)--Cambia Health Solutions (Cambia) and Blue Cross Blue Shield of North Dakota (BCBSND) today announced a strategic affiliation to better serve members with access to care that's simpler and more affordable — and remains close to home. The affiliation will unify all operations and enable the organizations to share best practices for local plan innovation and services, deliver personalized member experiences and leverage Cambia's robust technology infrastructure. Strategic affiliation to better serve members with access to care that's simpler and more affordable — and remains close to home. Share Established in 1995 by four Blue Cross Blue Shield licensees, Cambia is a nonprofit health solutions company that provides management and shared services for local Blue plans across the Pacific Northwest and Mountain West, all connected by a common focus on delivering more for members. 'Affiliating with Cambia allows us to leap ahead in the capabilities we can bring to the North Dakotans we serve,' said Dan Conrad, president and CEO of BCBSND. 'We both have a deep commitment to a strong local presence today and into the future. Backed by Cambia's national scale and resources, we can offer members and customers more affordable plan solutions and personalized health tools, all while continuing to be supported by local employees who understand their health care needs.' Cambia and BCBSND share a legacy of practical innovation and community commitment. Cambia's mission is to transform health care to work better for real people and be economically sustainable. It is a founding partner and investor in Echo Health Ventures, which seeks to invest in and grow great health care companies. The health solutions company brings experience offering high-quality, cost-effective health care through personalized member tools that make it easier for people to navigate their care. BCBSND contributes deep expertise and market leadership in rural health, Medicare and Medicaid solutions, and provider collaboration. 'Cambia works every day to make health care easier and lives better for our members. For decades we've proven that we can do more when we have partners who share in this work,' said Jared Short, president and CEO of Cambia. 'BCBSND's culture and vision fit perfectly as we work together to innovate and transform health care for the communities we serve.' Members retain their current coverage and will continue to use their BCBSND insurance card just as they do today. BCBSND will continue to offer Medicare Advantage through NextBlue of North Dakota. BCBSND will maintain its local plan name, board of directors, and philanthropic foundation. It will also continue its mutual status, meaning it will remain governed by voting policyholders rather than investors. All BCBSND's reserve funds and foundation resources remain in North Dakota. Cambia will also maintain its foundation, and local health plans will operate in Idaho, Oregon, Utah, and Washington, as they do now. The areas of focus for the affiliation include: Improving the care experience with more personalized and connected solutions for members and providers. The affiliation enables investment in care solutions such as advanced primary care, mobile platforms for on-demand and virtual primary care, expanded tools for maternal and family health, and programs tailored to local communities. The affiliation enables investment in care solutions such as advanced primary care, mobile platforms for on-demand and virtual primary care, expanded tools for maternal and family health, and programs tailored to local communities. Expanding capabilities and tools to meet the unique local health needs of members and communities. Shared technology and data will create new opportunities for plans to collaborate with providers, employers and communities to support care that is more accessible, understandable and actionable for members and providers. Shared technology and data will create new opportunities for plans to collaborate with providers, employers and communities to support care that is more accessible, understandable and actionable for members and providers. Investing in transformative, financially sound solutions to improve members' health outcomes. Combined resources across operations and technology will increase agility, expand plan capabilities, provide cost savings, and simplify the experience for members and customers. The strategic affiliation is subject to regulatory approval in North Dakota and is expected to close in 2026. For more information, visit the fact sheet. About Blue Cross Blue Shield of North Dakota BCBSND was founded in 1940 with the mission to provide members with affordable access to health care across the state. As an independent licensee of the Blue Cross and Blue Shield Association (BCBSA), BCBSND is committed to transforming care and health across the state to improve outcomes, lower cost trends and make it easier to shop, buy and use health care coverage. Members have access to unmatched local service and to a comprehensive network of health care providers across the state, the nation and more than 190 countries. About Cambia Health Solutions Cambia Health Solutions, headquartered in Portland, Oregon, is dedicated to transforming health care. We put people at the heart of everything we do as we work to make the health care system more economically sustainable and efficient for people and their families. Our company reaches millions of Americans nationwide, including more than 3.6 million people served by our regional health plans. To learn more about us, visit
CNBC
24 minutes ago
- CNBC
Telehealth firm Ro enlists Serena Williams as ambassador for weight-loss drugs
Telehealth company Ro has enlisted former tennis player Serena Williams as a celebrity patient ambassador for its weight-loss treatments, it said on Thursday. She will star in a national marketing campaign for GLP-1s medication and inspire others to take the support they need to reach their health goals, a company spokesperson said. Williams, who has won 23 grand slam titles, is speaking out for the first time about using GLP-1 weight-loss treatment to improve her health and help reach her weight goals after having children, Ro said. Her grand slams make Williams the most successful female tennis player in the modern era. She won the Australian Open in 2017 while she was pregnant. The company, which sells Eli Lilly's Zepbound and Novo Nordisk's Wegovy through its weight-loss program, said Williams' husband and co-founder of social media site Reddit, Alexis Ohanian, is an investor in Ro and serves on its board.
